sulfasalazine and Liver Neoplasms
sulfasalazine has been researched along with Liver Neoplasms in 13 studies
Sulfasalazine: A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907)
sulfasalazine : An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position.
Liver Neoplasms: Tumors or cancer of the LIVER.
Research Excerpts
| Excerpt | Relevance | Reference |
|---|---|---|
| " The aims of the present study were to assess: (i) expression status of CD44v9 and xCT in hepatocellular carcinoma (HCC) tissues, including those derived from patients treated with hepatic arterial infusion chemoembolization (HAIC) therapy with cisplatin (CDDP); and (ii) whether combination of CDDP with sulfasalazine (SASP), an inhibitor of xCT, was more effective on tumor cells than CDDP alone by inducing ROS-mediated apoptosis." | 7.88 | High expression of CD44v9 and xCT in chemoresistant hepatocellular carcinoma: Potential targets by sulfasalazine. ( Abe, M; Akiba, J; Ikezono, Y; Iwamoto, H; Kakuma, T; Koga, H; Masuda, A; Nakamura, T; Niizeki, T; Sakaue, T; Tanaka, T; Torimura, T; Wada, F; Yano, H, 2018) |
| "Malignant ascites in advanced hepatocellular carcinoma (HCC) is a complex clinical problem that lacks effective treatments." | 5.91 | Ferroptosis-Enhanced Immunotherapy with an Injectable Dextran-Chitosan Hydrogel for the Treatment of Malignant Ascites in Hepatocellular Carcinoma. ( Deng, S; Deng, Y; Hu, Y; Huang, J; Jin, H; Liao, Z; Liu, Y; Lovell, JF; Meng, J; Tian, Y; Tuo, Z; Yang, K; Yang, X; Zhou, Z, 2023) |
| "CD133-positive cells in hepatocellular carcinoma (HCC) exhibit cancer stem cell (CSC)-like properties as well as resistance to chemotherapeutic agents and ionizing radiation; however, their function remains unknown." | 5.46 | Sulfasalazine attenuates evading anticancer response of CD133-positive hepatocellular carcinoma cells. ( Bae, SM; Choi, EK; Jang, J; Kim, JS; Kim, KM; Myung, SJ; Seo, HR; Shin, TH; Song, Y, 2017) |
| " The aims of the present study were to assess: (i) expression status of CD44v9 and xCT in hepatocellular carcinoma (HCC) tissues, including those derived from patients treated with hepatic arterial infusion chemoembolization (HAIC) therapy with cisplatin (CDDP); and (ii) whether combination of CDDP with sulfasalazine (SASP), an inhibitor of xCT, was more effective on tumor cells than CDDP alone by inducing ROS-mediated apoptosis." | 3.88 | High expression of CD44v9 and xCT in chemoresistant hepatocellular carcinoma: Potential targets by sulfasalazine. ( Abe, M; Akiba, J; Ikezono, Y; Iwamoto, H; Kakuma, T; Koga, H; Masuda, A; Nakamura, T; Niizeki, T; Sakaue, T; Tanaka, T; Torimura, T; Wada, F; Yano, H, 2018) |
| "Malignant ascites in advanced hepatocellular carcinoma (HCC) is a complex clinical problem that lacks effective treatments." | 1.91 | Ferroptosis-Enhanced Immunotherapy with an Injectable Dextran-Chitosan Hydrogel for the Treatment of Malignant Ascites in Hepatocellular Carcinoma. ( Deng, S; Deng, Y; Hu, Y; Huang, J; Jin, H; Liao, Z; Liu, Y; Lovell, JF; Meng, J; Tian, Y; Tuo, Z; Yang, K; Yang, X; Zhou, Z, 2023) |
| "Sulfasalazine (SSZ) is an inhibitor of xCT and was shown to suppress the survival of CD44v-positive stem-like cancer cells both in vitro and in vivo." | 1.46 | Dose-escalation study for the targeting of CD44v ( Doi, T; Einaga, Y; Fukutani, M; Hasegawa, H; Hironaka, S; Imamura, CK; Ishii, Y; Kuwata, T; Nagano, O; Nakajima, TE; Nomura, S; Ohtsu, A; Ozeki, T; Sato, A; Saya, H; Shitara, K; Takahashi, S; Tsuchihashi, K, 2017) |
| "CD133-positive cells in hepatocellular carcinoma (HCC) exhibit cancer stem cell (CSC)-like properties as well as resistance to chemotherapeutic agents and ionizing radiation; however, their function remains unknown." | 1.46 | Sulfasalazine attenuates evading anticancer response of CD133-positive hepatocellular carcinoma cells. ( Bae, SM; Choi, EK; Jang, J; Kim, JS; Kim, KM; Myung, SJ; Seo, HR; Shin, TH; Song, Y, 2017) |
| " The underlying mechanism for TL-118-treatment success was associated with hepatic perfusion attenuation resulting from reduced nitric-oxide (NO) serum levels as elucidated by using hemodynamic response imaging (HRI, a functional MRI combined with hypercapnia and hyperoxia)." | 1.38 | Improved efficacy of a novel anti-angiogenic drug combination (TL-118) against colorectal-cancer liver metastases; MRI monitoring in mice. ( Abramovitch, R; Corchia, N; Edrei, Y; Gross, E, 2012) |
Research
Studies (13)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (7.69) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (15.38) | 29.6817 |
| 2010's | 6 (46.15) | 24.3611 |
| 2020's | 4 (30.77) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Chen, S | 1 |
| Zhang, L | 1 |
| Chen, Y | 1 |
| Fu, L | 1 |
| Meng, J | 1 |
| Yang, X | 1 |
| Huang, J | 1 |
| Tuo, Z | 1 |
| Hu, Y | 1 |
| Liao, Z | 1 |
| Tian, Y | 1 |
| Deng, S | 1 |
| Deng, Y | 1 |
| Zhou, Z | 1 |
| Lovell, JF | 1 |
| Jin, H | 1 |
| Liu, Y | 1 |
| Yang, K | 1 |
| Capelletti, MM | 1 |
| Manceau, H | 1 |
| Puy, H | 1 |
| Peoc'h, K | 1 |
| Shamaa, MM | 1 |
| Wada, F | 1 |
| Koga, H | 1 |
| Akiba, J | 1 |
| Niizeki, T | 1 |
| Iwamoto, H | 1 |
| Ikezono, Y | 1 |
| Nakamura, T | 1 |
| Abe, M | 1 |
| Masuda, A | 1 |
| Sakaue, T | 1 |
| Tanaka, T | 1 |
| Kakuma, T | 1 |
| Yano, H | 1 |
| Torimura, T | 1 |
| Anwar, DM | 1 |
| Khattab, SN | 1 |
| Helmy, MW | 1 |
| Kamal, MK | 1 |
| Bekhit, AA | 1 |
| Elkhodairy, KA | 1 |
| Elzoghby, AO | 1 |
| Shitara, K | 1 |
| Doi, T | 1 |
| Nagano, O | 1 |
| Imamura, CK | 1 |
| Ozeki, T | 1 |
| Ishii, Y | 1 |
| Tsuchihashi, K | 1 |
| Takahashi, S | 1 |
| Nakajima, TE | 1 |
| Hironaka, S | 1 |
| Fukutani, M | 1 |
| Hasegawa, H | 1 |
| Nomura, S | 1 |
| Sato, A | 1 |
| Einaga, Y | 1 |
| Kuwata, T | 1 |
| Saya, H | 1 |
| Ohtsu, A | 1 |
| Song, Y | 1 |
| Jang, J | 1 |
| Shin, TH | 1 |
| Bae, SM | 1 |
| Kim, JS | 1 |
| Kim, KM | 1 |
| Myung, SJ | 1 |
| Choi, EK | 1 |
| Seo, HR | 1 |
| Guo, W | 1 |
| Zhao, Y | 1 |
| Zhang, Z | 1 |
| Tan, N | 1 |
| Zhao, F | 1 |
| Ge, C | 1 |
| Liang, L | 1 |
| Jia, D | 1 |
| Chen, T | 1 |
| Yao, M | 1 |
| Li, J | 1 |
| He, X | 1 |
| Edrei, Y | 1 |
| Gross, E | 1 |
| Corchia, N | 1 |
| Abramovitch, R | 1 |
| Navarro, JT | 1 |
| Ribera, JM | 1 |
| Mate, JL | 1 |
| Granada, I | 1 |
| Juncà, J | 1 |
| Batlle, M | 1 |
| Millá, F | 1 |
| Feliu, E | 1 |
| Izumiya, M | 1 |
| Yajima, T | 1 |
| Serizawa, H | 1 |
| Watanabe, N | 1 |
| Hamada, Y | 1 |
| Tsunematsu, S | 1 |
| Kumagai, N | 1 |
| Tsuchimoto, K | 1 |
| Toyoda, H | 1 |
| Hibi, T | 1 |
| Ishii, H | 1 |
| STAUFFER, MH | 1 |
| SAUER, WG | 1 |
| DEARING, WH | 1 |
| BAGGENSTOSS, AH | 1 |
Reviews
3 reviews available for sulfasalazine and Liver Neoplasms
| Article | Year |
|---|---|
Inhibiting Sodium Taurocholate Cotransporting Polypeptide in HBV-Related Diseases: From Biological Function to Therapeutic Potential.
Topics: Carcinoma, Hepatocellular; Hep G2 Cells; Hepatitis B; Hepatitis B virus; Hepatocytes; Humans; Interf | 2022 |
Ferroptosis in Liver Diseases: An Overview.
Topics: alpha-Tocopherol; Animals; Autophagy; Chemical and Drug Induced Liver Injury; Cyclohexylamines; Cyst | 2020 |
[A case of Crohn's disease complicated with hepatocellular carcinoma].
Topics: Adult; Anti-Inflammatory Agents; Carcinoma, Hepatocellular; Crohn Disease; Drug Combinations; Drug T | 2003 |
Other Studies
10 other studies available for sulfasalazine and Liver Neoplasms
| Article | Year |
|---|---|
Ferroptosis-Enhanced Immunotherapy with an Injectable Dextran-Chitosan Hydrogel for the Treatment of Malignant Ascites in Hepatocellular Carcinoma.
Topics: Ascites; Carcinoma, Hepatocellular; Chitosan; Dextrans; Ferroptosis; Humans; Hydrogels; Immunotherap | 2023 |
Sulfasalazine synergistically enhances the inhibitory effects of imatinib against hepatocellular carcinoma (HCC) cells by targeting NFκB, BCR/ABL, and PI3K/AKT signaling pathway-related proteins.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Gene | 2021 |
High expression of CD44v9 and xCT in chemoresistant hepatocellular carcinoma: Potential targets by sulfasalazine.
Topics: Aged; Aged, 80 and over; Amino Acid Transport System y+; Animals; Apoptosis; Carcinoma, Hepatocellul | 2018 |
Lactobionic/Folate Dual-Targeted Amphiphilic Maltodextrin-Based Micelles for Targeted Codelivery of Sulfasalazine and Resveratrol to Hepatocellular Carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Disaccharides; Drug Delivery Systems; Fol | 2018 |
Dose-escalation study for the targeting of CD44v
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Cell Proliferation; Dose-Re | 2017 |
Sulfasalazine attenuates evading anticancer response of CD133-positive hepatocellular carcinoma cells.
Topics: AC133 Antigen; Animals; Carcinoma, Hepatocellular; Cell Culture Techniques; Cell Line, Tumor; Drug R | 2017 |
Disruption of xCT inhibits cell growth via the ROS/autophagy pathway in hepatocellular carcinoma.
Topics: Amino Acid Transport System y+; Animals; Autophagy; Carcinoma, Hepatocellular; Cell Growth Processes | 2011 |
Improved efficacy of a novel anti-angiogenic drug combination (TL-118) against colorectal-cancer liver metastases; MRI monitoring in mice.
Topics: Angiogenesis Inhibitors; Animals; Cimetidine; Colorectal Neoplasms; Cyclophosphamide; Diclofenac; Di | 2012 |
Hepatosplenic T-gammadelta lymphoma in a patient with Crohn's disease treated with azathioprine.
Topics: Adrenal Cortex Hormones; Adult; Antineoplastic Combined Chemotherapy Protocols; Autoimmune Diseases; | 2003 |
THE SPECTRUM OF CHOLESTATIC HEPATIC DISEASE.
Topics: Adolescent; Alkaline Phosphatase; Aspartate Aminotransferases; Bile Duct Neoplasms; Bilirubin; Blood | 1965 |